Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company's shares to drop massively in after-hours trading ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...

Neurogene Inc.’s NGNE share price has dipped by 18.34%, which has investors questioning if this is right time to buy.

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on ...

Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Neurogene in a research ...

EDT Neurogene (NGNE) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing ...

Neurogene Inc. (NASDAQ:NGNE) is an important biotech to watch during this year, and it is because it is gearing up for two key catalysts that investors need to keep an eye on. The first of which ...

Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing its ...